Redwood City, CA – March 5, 2019 – Gynesonics, a women’s healthcare company and the developer of the Sonata® system for the treatment of uterine fibroids (also known as leiomyomas) today announced the publication of the VITALITY study in the Journal of Gynecologic Surgery. The article, “Long-Term Clinical Outcomes [...]
MINNEAPOLIS, Feb. 11, 2019 /PRNewswire/ — Nuvaira, a developer of novel therapeutic medical devices to treat obstructive lung diseases, announced today it has closed a $79 million equity financing led by U.S. Venture Partners, with Endeavour Vision, Qiming Venture Partners, Lightstone Ventures and Richard King Mellon Foundation joining the [...]
Intracept® Procedure Demonstrates Highly Significant Treatment Effect vs. Non-Surgical Management MINNEAPOLIS – January 30, 2019 – Relievant Medsystems, a privately‐held medical device company, developing minimally‐invasive solutions for chronic low back pain (CLBP), today announced that a pre‐specified interim analysis of the Level I INTRACEPT Randomized Controlled Trial (RCT) found [...]
Redwood City, CA – January 10, 2019 – Gynesonics, a women’s healthcare company and the developer of the Sonata® system for the treatment of uterine fibroids (also known as leiomyomas) today announced the publication of the SONATA IDE Pivotal Trial 12-month results in the January edition of Obstetrics and [...]
JANUARY 8TH, 2019 – MINNEAPOLIS, MN Relievant Medsystems, a privately-held medical device company developing minimally-invasive solutions for chronic low back pain (CLBP), today announced that the Centers for Medicare & Medicaid Services (CMS) has established Healthcare Common Procedure Coding System (HCPCS) codes C9752 and C9753 for the Intracept Procedure [...]
SOPHiA GENETICS raises $77 million to accelerate the democratization of data-driven medicine San Francisco, Jan. 4, 2019: SOPHiA GENETICS, a leading health tech company, announced today the closing of a $77 million investment round to accelerate the democratization of Data- Driven Medicine. The round was led by Generation [...]
Redwood City, CA – January 3, 2019 – Gynesonics, a women’s healthcare company and the developer of the Sonata System and other advanced, incision-free solutions for the treatment of uterine conditions, today announced that it has completed a $75 million equity financing. The financing was led by Bain Capital [...]
Parties Will Jointly Develop MP0310, a Pre-clinical FAP x 4-1BB MultiSpecific DARPin® Molecule, in Combination with Amgen’s Oncology Assets, Including BiTE® Molecules Molecular Partners Retains Rights to Develop MP0310 in Combination With its Pipeline Products ZURICH-SCHLIEREN, SWITZERLAND and THOUSAND OAKS, Calif.– (Dec. 19, 2018) – Molecular Partners AG (SIX: [...]
Located in Basel, Switzerland, Medartis develops, manufactures and distributes medical internal fixation devices and surgical instruments offered in system solutions for small bone fractures focusing on the extremities. The company was founded in 1997 by Dr. Thomas Straumann and employs more than 500 people on 12 sites, and its [...]
Advanced technology offers potential to become a new standard of care for fibroid treatment Redwood City, CA – August 22, 2018 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, today announced that it has received 510(k) clearance from the U.S. [...]